



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute	e for form 1449A/PTO			d	omplete if Known	
	INFORMATION DIS	SCLOSU	DE	Application Number	Unassigned	
1				Filing Date	<u>Herewith</u>	
	STATEMENT BY A	PPLICA	NT	First Named Inventor	LITTLE, DAVID G.	
ł				Group Art Unit	Unassigned	
	(use as many sheets a	s necessary	<i>)</i>	Examiner Name	Unassigned	
Sheet	1	of	11	Attorney Docket Number	RICE-006	

	•			U.S. PATENT DOCUM	MENTS	
Examiner Initials'	Cite No. ¹	U.S. Pate	nt Documents Kind Code ² (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear

Examiner	Cite No. ¹	Fore	ign Patent Documents	Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials'		Office ³	Number ⁴ Kind Code ⁴ (if known)		of Cited Document MM-DD-YYYY		⊤ ⁵
	Bl	wo	93/11786	Procter & Gamble Pharmaceuticals, Inc.	06/24/1993		
	B2	WÒ	94/21266	Leiras Oy	09/24/1994		
	B3	WO	95/28936	Merck & Co., Inc.	11/02/1995		
	B4 9	w	96/39150	Merck & Co., Inc.	12/12/1996		
	B5	wo	96/39151	Merck & Co., Inc.	12/12/1996		
, , , , , , , , , , , , , , , , , , , ,	В6	wo	98/00438	The University of Liverpool	01/08/1998		\top

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	1 . 1						
Examiner Signature		Date Considered	· · · · · · · · · · · · · · · · · · ·				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

+ 1

PTO/SB/08A (08-00) proved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Tra Jemark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

Attorney Docket Number

stitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

1

ı

Application Number 10/049,556

Filing Date February 12, 2002
Intern. Application Number PCT/AU00/00982
Intern. Filing Date 08/17/00

First Named Inventor DAVID G. LITTLE

Group Art Unit Unassigned

Examiner Name Unassigned

RICE006

Complete if Known

	•			U.S. PATENT DOCUM	MENTS	
Examiner Initials'	Cite No.¹	U.S. Par Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear

					FOREIGN PATENT DOCUME	NTS		
Examin	Cite	Foreign Patent Documents			Name of Patentee or	Date of Publication	Pages, Columns, Lines,	
er Initials'	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵
		В7	WO96/39	9150A	Merck & Co., Inc.	12/12/1996		

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
·	C1	ABSTRACT: LOMBARDI, entitled "Clinical trails with bisphosphonates" Ann Ital Med Int. 1992 Jul-Sep; 7(3 Suppl): 158S-165S.	
	C2	GOODSHIP et al., entitled "Use of Bisphosphonate (pamidronate) to modulate fracture repair in ovine bone," Ann Oncology 1994; 5 Suppl 7:S53-5.	
	C3	LI et al. entitled "Effect of Bisphosphonate (Incadronate) on Fracture Healing of Long Bones in Rats," J Bone Miner Res. Vol. 14, Number 6, (1999): 969-79.	
	C4	RUSSELL et al., entitled "Bisphosphonates: from the laboratory to the clinic and back again," Bone 1999 Jul: 25(1):97-106	
	C5	GLORIEUX et al., entitled "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta," N. Engl. J Med 1998: Number 14, 339:947-52	
-	C6	RAGGIO et al. entitled, "Alendronate reduces fractures without increasing bone strength in a growing mouse model of osteogenesis imperfecta," Proceedings of Paediatric Orthopaedic Society of North America May 1999. (Paper No. 66)	
	C7	GIULIANI et al., entitled "Bisphosphonates Stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo," Bone 1998, May; Vol. 22 (5): 455-61.	
	C8	MAYOR P., et al., entitled "Zolendroic acid is superior to pamidronate in the treatment of tumour-induced hypercalcaemia: a pooled analysis," Journal of Clinical Oncology, Vol. 19, No. 2, January 15, 2001: pp. 558-567	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Pleastype a plus sign (+) inside this box → . +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Solder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449A/PTO			C	omplete if Known
				Application Number	10/049,556
	INFORMATION DISCI	.osi	JRE	Filing Date	May 7, 2002
	STATEMENT BY APP	LIC	ANT	First Named Inventor	LITTLE, DAVID GRAHAM
				Group Art Unit	1617
	(use as many sheets as ne	cessai	γ)	Examiner Name	CRIARES, THEODORE J.
Sheet	1	of	1	 Attorney Docket Number	RICE-006

Examin er Initials'	Cite No. ¹	U.S. Patent Documents Number Kind Code (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		5,853,759	Katdare et al.	12-29-1998	

Examiner Initials'	Cite No. ¹	Fore	ign Patent D		REIGN PATENT DOCUME Name of Patentee or	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Documents			Τ*

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	·							
	·							
**								
-								

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.